Endothelin-1 and Anticardiolipin Antibodies in Primary Biliary Cholangitis Patients with Portal Hypertension: A Pilot Retrospective Study.
- 1Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.
- 2Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Roentgena 5, 02-781 Warsaw, Poland.
- 3Faculty of Chemistry, University of Warsaw, L. Pasteura 1, 02-093 Warsaw, Poland.
Abstract
Primary biliary cholangitis (PBC) is a chronic autoimmune, cholestatic liver disease leading to fibrosis, cirrhosis, and portal hypertension. Endothelin-1 (ET-1), a potent vasoconstrictor with profibrotic properties, has been implicated in the pathogenesis of liver fibrosis and portal hypertension. Anti-cardiolipin antibodies (aCL) may further contribute to disease progression by promoting thrombotic complications. Our aim was to evaluate serum ET-1 concentrations and anti-cardiolipin antibody levels in PBC patients and their association with portal hypertension. Serum samples from 80 patients with PBC, including patients with portal hypertension, and 25 healthy controls were analyzed. ET-1 concentrations and anti-cardiolipin antibodies were measured using commercially available immunoassays. Elevated serum ET-1 levels were detected in 84% of patients with PBC and portal hypertension and the ET-1 concentrations were also significantly higher in this group compared to the control group. Serum ET-1 levels positively correlated with total bilirubin concentrations and the severity of histological fibrosis. Anti-cardiolipin antibodies were detected in 32% of PBC patients with portal hypertension. Elevated serum ET-1 concentrations and the presence of anti-cardiolipin antibodies are associated with advanced liver disease and portal hypertension in patients with PBC. These biomarkers may have potential value in identifying patients at increased risk of disease progression and worsening liver function.
Related
- Endothelin antagonism: a new era for resistant hypertension
- Functional activity of anti-endothelin type A receptor antibodies as a predictive tool of allograft injury in pediatric kidney transplantation
- Machine learning and nomogram for predicting severity of acute cholangitis: development and internal validation of a dual-framework model in a retrospective cohort study.
- High-fat diet and portal hypertension: a triangulation approach combining Mendelian randomization with retrospective clinical analysis
- Effect of Anti-thyroid Peroxidase Antibodies on Assisted Reproductive Technologies Outcomes: A Retrospective Cohort Study.
BibTeX
@article{bauer2026endothelin1,
title = {{Endothelin-1 and Anticardiolipin Antibodies in Primary Biliary Cholangitis Patients with Portal Hypertension: A Pilot Retrospective Study.}},
author = {Alicja Bauer and Tomasz Rawa and Tomasz Bauer},
journal = {International journal of molecular sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198461},
url = {https://europepmc.org/article/MED/42883709},
note = {CC BY},
}
RIS
TY - JOUR
TI - Endothelin-1 and Anticardiolipin Antibodies in Primary Biliary Cholangitis Patients with Portal Hypertension: A Pilot Retrospective Study.
AU - Alicja Bauer
AU - Tomasz Rawa
AU - Tomasz Bauer
PY - 2026
DA - 2026/09/23
JO - International journal of molecular sciences
DO - 10.3390/ijms27198461
UR - https://europepmc.org/article/MED/42883709
AB - Primary biliary cholangitis (PBC) is a chronic autoimmune, cholestatic liver disease leading to fibrosis, cirrhosis, and portal hypertension. Endothelin-1 (ET-1), a potent vasoconstrictor with profibrotic properties, has been implicated in the pathogenesis of liver fibrosis and portal hypertension. Anti-cardiolipin antibodies (aCL) may further contribute to disease progression by promoting thrombotic complications. Our aim was to evaluate serum ET-1 concentrations and anti-cardiolipin antibody levels in PBC patients and their association with portal hypertension. Serum samples from 80 patients with PBC, including patients with portal hypertension, and 25 healthy controls were analyzed. ET-1 concentrations and anti-cardiolipin antibodies were measured using commercially available immunoassays. Elevated serum ET-1 levels were detected in 84% of patients with PBC and portal hypertension and the ET-1 concentrations were also significantly higher in this group compared to the control group. Serum ET-1 levels positively correlated with total bilirubin concentrations and the severity of histological fibrosis. Anti-cardiolipin antibodies were detected in 32% of PBC patients with portal hypertension. Elevated serum ET-1 concentrations and the presence of anti-cardiolipin antibodies are associated with advanced liver disease and portal hypertension in patients with PBC. These biomarkers may have potential value in identifying patients at increased risk of disease progression and worsening liver function.
SN - 1422-0067
ER -